HK Stock Market Move | HBM HOLDINGS-B (02142) rose over 4%, with first-half revenue increasing by more than 20% compared to the same period last year, continuously validating the company's platform value through business development.

HBM HOLDINGS-B (02142) has risen over 4%, currently up 4.31% at HK$15.02, with a trading volume of HK$115 million. In the news, HBM HOLDINGS-B recently announced its interim results for the six months ending on June 30, 2026, reporting revenue of US$122 million, a year-on-year increase of 20.9%. According to the announcement, total revenue for the reporting period was US$122 million, up 20.9% from US$101 million in the first half of 2025. Revenue from royalties and cooperation increased from US$93.7 million to US$113 million, primarily due to ongoing strategic partnerships with leading multinational pharmaceutical companies and the licensing and cooperation of innovative products. In addition, revenue from research services and technology licensing fees grew by 23.8% from US$7.6 million to US$9.4 million. CITIC Securities research report pointed out that HBM HOLDINGS-B's performance in the first half exceeded the firm's expectations, mainly driven by the overseas licensing of CTLA-4, which boosted revenue. CITIC noted that the company is shifting from single product licensing to a model combining platform cooperation, product licensing, and joint development. Continuous business development validates the company's platform value, but cooperation revenue still accounts for over 90%, and performance may fluctuate with the pace of transactions and revenue recognition. Additionally, the company's first AI-driven weight loss candidate LET003, when used in combination with semaglutide, has shown potential in enhancing fat loss and preserving lean body mass in preclinical studies, with plans to submit an IND in Q3 2026.